
ImmunoGenesis
Develops science-driven immune therapies specifically designed to treat tumors lacking activated T cells or having other immune resistance mechanisms.
Employees
Enterprise value
$18—27m
Get premium to view all results
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor investor | €0.0 | round |
investor | €0.0 | round | |
* | $4.5m | Early VC | |
Total Funding | 000k |
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads